Evidence map›Paper›PMID 36711108›Full record

ArticleEuropean Medical Journal (Chelmsford, England)2020

Longitudinal Characterisation of the Gastrointestinal Tract Microbiome in Systemic Sclerosis.

Elizabeth R Volkmann, Anna-Maria Hoffmann-Vold, Yu-Ling Chang, Venu Lagishetty, Philip J Clements, Øyvind Midtvedt, Øyvind Molberg, Jonathan Braun, Jonathan P Jacobs

Open access · diamondAbstract read
In one paragraph

Article in European Medical Journal (Chelmsford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Is there a role for the microbiome in systemic sclerosis?Expert review of clinical immunology · 2023
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Elizabeth R VolkmannDepartment of Medicine, University of California, David Geffen School of Medicine, Los Angeles, California, USA.
Anna-Maria Hoffmann-VoldDepartment of Rheumatology, Oslo University Hospital, Oslo, Norway.
Yu-Ling ChangDepartment of Pathology and Laboratory Medicine, University of California, David Geffen School of Medicine, Los Angeles, California, USA.
Venu LagishettyThe Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, California, USA.
Philip J ClementsUniversity of California, David Geffen School of Medicine, Los Angeles, California, USA.
Øyvind MidtvedtDepartment of Rheumatology, Oslo University Hospital, Oslo, Norway.
Øyvind MolbergDepartment of Rheumatology, Oslo University Hospital, Oslo, Norway.
Jonathan BraunDepartment of Medicine, Cedars Sinai Medical Center, Los Angeles, California, USA.
Jonathan P JacobsThe Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, California, USA.
Oslo University Hospital · NOUniversity of California, Los Angeles · USCedars-Sinai Medical Center · USVA Greater Los Angeles Healthcare System · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Using polygenic scores to enhance both variant discovery, and understanding of functional consequences of genetic variation in IBD.P01DK046763 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI TARGAN, STEPHAN R. · 1992 to 2020
$31.1M
Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
CSRD VA IK2 CX001717NCATS NIH HHS UL1 TR001881NIDDK NIH HHS P01 DK046763NIDDK NIH HHS P30 DK041301
6 · The paper itself

Abstract

Objectives: To evaluate changes in microbial composition and the evolution of gastrointestinal tract (GIT) symptoms in systemic sclerosis (SSc). Methods: Adult SSc patients provided stool specimens every 3 months over the course of 1 year. Participants completed the University of California, Los Angeles (UCLA) GIT 2.0 questionnaire to assess GIT symptom severity at each stool collection. The microbiota from these samples were determined by Illumina HiSeq 2500 16S ribosomal RNA sequencing (Illumina, Inc., San Diego, California, USA). Mixed effect models evaluated changes in GIT symptoms and microbial composition over time. Results: Among 19 patients with SSc (female; 89.5%; median age: 51.3 years), the median disease duration was 7 years and the baseline total GIT 2.0 score was 0.7 (standard deviation: 0.6). The majority of participants (63%) provided at least four stool samples over the course of the 12-month study. Patients with longer disease durations had increased GIT symptoms over the course of the study. There was no difference in the course of GIT symptoms over time between patients with limited versus diffuse cutaneous disease. The relative abundances of specific genera did not change over time within individual subjects. After controlling for age, sex, ethnicity, disease duration, and SSc subtype (i.e., limited versus diffuse), low abundance of Conclusion: This study is the first to have longitudinally characterised the lower GIT microbiome in SSc patients and demonstrated relative stability of genera abundance over the course of 1 year. The findings provide additional evidence that specific genera are associated with SSc-GIT symptoms and warrant further evaluation in larger SSc studies.

Indexed as

dysbiosisgastrointestinal tract (GIT)microbiotaSystemic sclerosis (SSc)

Identifiers

PMID36711108
PMCPMC9881192
OpenAlexW3174591592

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.